L

LabCorp

Global life sciences R&D services

Lead IT Business Analyst

Full-TimeUpdated on 10/20/2026
No salary listed
Expert
Bachelor's, MBA
Durham, NC, USA+1 moreMore locations: Burlington, NC, USA
HybridHybrid work in Burlington and Durham, North Carolina.
Business & StrategyBusiness Analysis

About the job

Requirements
  • A bachelor's degree is required.
  • At least 8 years of experience in business analysis, business systems analysis, systems analysis, and technology solutions is required.
  • At least 8 years of experience analyzing complex business and technical requirements and translating business needs into technology solutions is required.
  • At least 8 years of experience supporting enterprise-scale technology implementations, system enhancements, modernization initiatives, or business process improvement efforts is required.
  • At least 8 years of experience leading business analysis activities for complex, cross-functional initiatives involving multiple business and technology stakeholders is required.
  • At least 8 years of experience evaluating business processes, systems, and solution options and providing recommendations aligned with business objectives and technology strategy is required.
  • At least 8 years of experience partnering with business leaders, technology teams, product owners, architects, and project teams to support solution delivery and achieve strategic and operational objectives is required.
  • At least 8 years of experience facilitating stakeholder discussions, managing requirements and scope, and influencing decisions across diverse stakeholder groups is required.
  • Demonstrated ability to lead complex business and systems analysis efforts and align business needs with effective technology and process solutions is required.
  • Ability to assess complex business challenges, evaluate solution options, and develop recommendations that improve operational effectiveness and business outcomes is required.
  • Advanced ability to define, analyze, and manage business and technical requirements, processes, dependencies, and solution objectives across complex initiatives is required.
  • Ability to build partnerships, facilitate alignment, and influence decisions across diverse business, technology, and cross-functional stakeholders is required.
  • Strong written and verbal communication skills, including the ability to communicate requirements, recommendations, risks, impacts, trade-offs, and strategic considerations to technical and non-technical audiences, are required.
  • Ability to evaluate technology solutions in the context of business objectives, operational needs, risks, and enterprise priorities is required.
  • Demonstrated ability to provide guidance, coaching, and mentorship to Business Analysts while promoting consistent analysis standards and best practices is required.
  • Ability to navigate ambiguity, manage competing priorities, and identify opportunities to improve business analysis practices, processes, and organizational effectiveness is required.
Responsibilities
  • Lead business analysis activities for large-scale, complex, cross-functional technology initiatives, including application enhancements, system implementations, modernization efforts, and process improvements.
  • Partner with business and IT leadership to understand strategic objectives, evaluate solution options, assess impacts and trade-offs, and recommend approaches that support business and technology outcomes.
  • Lead requirements discovery and analysis through stakeholder interviews, workshops, and other elicitation techniques, translating complex business needs into functional and non-functional requirements, user stories, use cases, and acceptance criteria.
  • Analyze current-state business processes, systems, workflows, and data flows to identify gaps, risks, dependencies, and opportunities for improvement, and define future-state processes and business solutions.
  • Manage requirements throughout the project lifecycle, ensuring they are complete, traceable, testable, prioritized, and aligned with business objectives, while managing scope and requirement changes.
  • Collaborate with product owners, architects, engineering teams, project leaders, and other cross-functional partners to evaluate solution designs, refine backlogs, support delivery, and ensure solutions meet business and technical requirements.
  • Facilitate communication and alignment between business and technology stakeholders, translate complex concepts for technical and non-technical audiences, and address risks, issues, dependencies, and competing priorities.
  • Develop and maintain business analysis deliverables, including business requirements, process models, solution specifications, data flows, decision documentation, and supporting materials.
  • Support solution validation and implementation activities, including requirements coverage, test case review, user acceptance testing, defect triage, change readiness, training, and post-implementation evaluation.
  • Contribute to technology roadmap planning, initiative prioritization, portfolio-level decision-making, and continuous improvement across business systems and technology capabilities.
  • Establish and promote business analysis standards, methodologies, tools, templates, and best practices to improve quality and effectiveness across initiatives.
  • Provide leadership, mentorship, and guidance to Business Analysts through coaching, deliverable reviews, knowledge sharing, and development of business analysis capabilities.
  • Serve as a subject matter expert and trusted advisor on complex business systems initiatives, helping stakeholders navigate ambiguity, evaluate alternatives, and make informed decisions that drive measurable business value.
Desired Qualifications
  • An MBA or degree in Computer Science, Data Science, Engineering, Information Technology, or Business Administration is preferred.
  • At least 8 years of experience supporting enterprise transformation, technology modernization, operational excellence, or strategic business initiatives within complex organizations is preferred.
  • At least 8 years of experience with solution governance, technology portfolio planning, organizational change management, or enterprise process improvement initiatives is preferred.
  • At least 8 years of experience mentoring and developing Business Analysts and guiding complex analysis activities and deliverables is preferred.
  • At least 8 years of experience establishing or improving business analysis standards, methodologies, tools, documentation practices, and organizational best practices is preferred.
  • At least 8 years of experience working in large, complex, cross-functional, or highly matrixed environments and partnering with business and technology stakeholders at multiple levels is preferred.

About the company

L

LabCorp

View
Website

Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.

Company Size

10,001+

Company Stage

IPO

Headquarters

Burlington, Vermont

Founded

1976

Get referred to LabCorp

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 30, 2026 Q2 revenue rose 5.8% and adjusted EPS rose 14.9%.
  • Sept. 10, 2026 management kept 2026 revenue guidance at $14.71-$14.83 billion.
  • Labcorp targets 5% to 8% annual revenue growth through 2029 after integrating MLM.

What critics are saying

  • CMS cuts lab reimbursement up to 15% from Jan. 1, 2027, crushing diagnostics margins.
  • Sept. 24, 2026 Labcorp accepted a $2.3 million multistate AMCA breach settlement and vendor controls.
  • Bedford, Massachusetts layoffs began Mar. 9, 2026, showing lab footprint rationalization and demand softness.

What makes LabCorp unique

  • Sept. 8, 2026 MLM acquisition gives Labcorp wholly owned labs across four continents.
  • Sept. 10, 2026 investor day framed Labcorp as diagnostics, biopharma, science, and technology.
  • Labcorp supported over 85% of FDA-approved new drugs and therapies in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • Unlimited Paid Time Off
  • Tuition Reimbursement
  • Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Traders Agency
Oct 16th, 2026
Labcorp to acquire BioReference Health clinical, women's health and urology testing assets from OPKO for $722 million.

Labcorp to acquire BioReference Health clinical, women's health and urology testing assets from OPKO for $722 million. Traders Agency Team The Traders Agency editorial team delivers daily market anal... Follow Traders Agency on Google. Add Traders Agency, LLC as a preferred source so its market analysis shows up more in your Search and AI results. Labcorp and OPKO Health announced on October 15, 2026 that Labcorp has agreed to acquire select assets of BioReference Health, LLC, OPKO's wholly owned laboratory subsidiary, for $722 million in cash at closing, with the price subject to adjustment based on closing business revenues, plus up to an additional $150 million tied to future revenue from BioReference's 4Kscore prostate cancer test, according to a joint press release from the two companies. Deal terms and potential value. The $722 million cash component and the $150 million 4Kscore earnout together put the transaction's maximum potential value at $872 million, as reported by Medical Device Developments. Using the figures disclosed by the companies, its calculation shows the cash payment exceeds the earnout by $572 million ($722 million minus $150 million), or roughly 381% more than the contingent payment ((722 − 150) / 150 x 100). As an interpretation of that arithmetic, the upfront cash represents the bulk of the deal's value, with the earnout functioning as a smaller, performance-linked add-on; it is a comparison of the two disclosed amounts, not a forecast of what will ultimately be paid. Neither company's release specified the revenue thresholds or measurement period required to trigger the full $150 million 4Kscore earnout, nor did they disclose how the base $722 million price might be adjusted up or down based on BioReference's revenue at the time of closing. What Labcorp is acquiring. Labcorp will acquire BioReference's laboratory testing businesses focused on clinical and women's health testing services, urology, and diagnostic services provided to correctional institutions, along with certain operational assets including more than 80 additional patient service centers, per the joint announcement. Also included is BioReference's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision. According to Medical Device Developments, the 4Kscore test secured FDA approval in 2021 after being available as a laboratory-developed test since 2014, and it assesses the probability of finding aggressive prostate cancer in men 45 or older with an age-stratified elevated PSA or a positive nodule on a digital rectal examination. The same outlet reported that OPKO's diagnostics segment generated $74.5 million in revenue in the second quarter, of which the 4Kscore test contributed $6.3 million, though the companies' releases did not break out what share of OPKO's overall diagnostics revenue or earnings the divested BioReference businesses represent, or what remains at OPKO after the deal closes. Rationale from both sides. OPKO Chairman and CEO Phillip Frost framed the sale as a step toward concentrating on drug development, saying, "This transaction will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business," according to the joint release. The statement did not specify how OPKO intends to deploy the cash proceeds, such as through debt reduction, pipeline funding or share repurchases. On Labcorp's side, Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp, said the acquisition "strengthens our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers around the country," according to a PR Newswire version of the announcement. Labcorp expects the acquired business to generate approximately $250 million in revenue in the first year after close, based on its current post-closing forecasts, the companies said. Closing timeline and advisors. The transaction is subject to regulatory approvals and customary closing conditions. The companies said there will be no changes to operations or services and that both will continue to operate independently until closing; neither release specified an expected closing date. According to the joint release, Lazard is serving as Labcorp's financial advisor, with Hogan Lovells Cadwalader US LLP as lead transaction counsel and Parker Poe as real estate counsel. Piper Sandler & Co. is serving as OPKO's exclusive financial advisor, with Greenberg Traurig P.A. as legal counsel. Analyst reaction. According to Yahoo Finance, Evercore ISI analysts said the deal fits Labcorp's strategy of expanding in higher-growth specialty testing, writing that "women's health strengthens the specialty offering, while 4Kscore adds a differentiated asset with an opportunity for broader distribution rather than simply more routine testing volume." William Blair analysts, cited in the same report, called the 4Kscore test a "particularly compelling asset" with opportunity for broader adoption, saying it could help identify patients for further evaluation and avoid unnecessary biopsies. These are the analysts' own characterizations and not independently verified projections. Bottom line. The agreement adds a defined set of clinical, women's health, urology and corrections testing operations plus the 4Kscore prostate test to Labcorp's network, with Labcorp projecting roughly $250 million in first-year revenue from the assets. The companies have not disclosed a closing date, the specific 4Kscore earnout thresholds, or how OPKO plans to use the proceeds, and both releases caution that timing, final purchase price and earnout outcomes remain subject to regulatory approval and other conditions outside either company's control. Related reading. DISCLAIMER: Traders Agency does not offer financial advice. The information provided is for educational purposes only and should not be considered financial advice. Traders Agency is not responsible for any financial losses or consequences resulting from the use of the information provided. Trading carries inherent risks and may not be suitable for all individuals. You are advised to conduct your own research and seek personalized advice before making any investment decisions, recognizing the potential risks and rewards involved. See more from Traders Agency on Google. Make Traders Agency, LLC a preferred source and its market analysis will appear more prominently in your Google Search, Top Stories, and AI results. The Traders Agency editorial team delivers daily market analysis, stock research, and trading education. Its team of analysts covers stocks, options, crypto, commodities, and macroeconomics to help traders make informed decisions. Join the Edge Stop watching. Start winning. 50,000+ traders get its daily brief before the market opens. Free. No spam. Unsubscribe anytime.

PR Newswire
Oct 15th, 2026
Labcorp enters into agreement with OPKO Health to acquire select assets of BioReference Health.

Labcorp enters into agreement with OPKO Health to acquire select assets of BioReference Health. Oct 15, 2026, 07:30 ET Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ - Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets, including over 80 additional patient service centers. As part of the agreement, Labcorp will also acquire BioReference Health's proprietary 4Kscore(R) Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision, making this important test more broadly available to patients across the country. When complete, the transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, including a broad specialty testing menu, convenient patient service center network and robust data analytics and digital tools. "This acquisition strengthens our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers around the country," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By expanding our clinical, women's health, urology and corrections testing capabilities and broadening access to innovative diagnostics such as the FDA-approved 4Kscore Test, we can help providers make more informed decisions, improve patient care and increase access to the comprehensive laboratory services people need to live healthier lives." "This transaction will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. "Labcorp's national scale and capabilities will broaden patient and provider access to BioReference's 4Kscore Test to many more patients across the country. We believe this transaction is an important catalyst to further unlock additional value for our shareholders." The purchase price for the transaction is $722 million in cash at closing, subject to an upward or downward adjustment (if any) based on closing business revenues, and up to an additional $150 million in an earnout based on revenue from the 4Kscore Test. Labcorp expects the business revenue to be approximately $250 million in the first year after close, based on Labcorp's current post-closing forecasts. This transaction is subject to regulatory approvals and customary closing conditions. Until the transaction closes, there will be no changes to operations or services, and both companies will continue to operate independently. Lazard is serving as Labcorp's financial advisor, Hogan Lovells Cadwalader US LLP is serving as lead transaction counsel and Parker Poe is serving as real estate counsel. Piper Sandler & Co. is serving as OPKO's exclusive financial advisor, and Greenberg Traurig P.A. is serving as legal counsel. About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com. About OPKO OPKO Health, Inc. (Nasdaq: OPK) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements with respect to (a) the anticipated impact of the transaction including expanding access to comprehensive, high-quality laboratory services, (b) increased access to testing services and expanded testing capabilities including with respect to the 4Kscore Test, (c) anticipated timing to closing, final purchase price, post-closing revenue, and earnout for the 4Kscore Test, (d) other anticipated potential benefits of the acquisition to Labcorp and OPKO Health, and (e) required regulatory approvals and customary closing conditions. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the control of Labcorp or OPKO Health. These factors, in some cases, have affected and in the future (together with other factors) could affect the ability of Labcorp or OKPO Health to implement its respective business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. Neither Labcorp nor OPKO Health has any obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in each of Labcorp's and OPKO Health's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the headings RISK FACTORS and MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, and in each of Labcorp's and OPKO Health's other filings with the SEC. SOURCE Labcorp Holdings Inc

PR Newswire
Oct 13th, 2026
Labcorp and Thrive Global launch Thrive 5 test pairing lab insights with daily habit coaching

Labcorp has launched the Thrive 5 Health Test, its first lab test developed with Arianna Huffington's behaviour change company, Thrive Global. The test is sold through Labcorp OnDemand. It measures five cardiometabolic indicators: ApoB, hs-CRP, HbA1c, blood pressure, and body mass index. Consumers book testing at select Labcorp patient service centres across the US. Results arrive through Labcorp's patient portal and MyLabcorp mobile app, along with educational content and Thrive Microsteps. These are small daily actions on food, movement, sleep, stress, and connection. "Too often, we get information about our health without guidance on what to do about it," said Huffington, Thrive Global's founder and chief executive officer.

Communities News LLC
Sep 25th, 2026
Alaska asks court to approve its share of $2.3 million Labcorp data breach settlement.

Alaska asks court to approve its share of $2.3 million Labcorp data breach settlement. Alaska has asked an Anchorage judge to approve its part of a $2.3 million multistate settlement with Labcorp over a 2019 data breach at the medical testing company's debt collector, which potentially exposed information on 10.2 million Labcorp patients nationwide. Acting Attorney General Cori Mills's office filed the petition Thursday in Anchorage Superior Court, the same day a coalition of 44 attorneys general, including Alaska's, announced the settlement. State law requires court approval for this kind of agreement, in which a company promises to change its practices. The agreement is not an admission of wrongdoing, and the attorney general can reopen the matter later. The breach happened at American Medical Collection Agency, the business name of Retrieval-Masters Creditors Bureau, which Labcorp used to collect medical debts. Someone had unauthorized access to the collector's system from Aug. 1, 2018, through March 30, 2019. The breach potentially exposed information on more than 27.5 million people across all of the collector's clients, including 10.2 million Labcorp patients. Labcorp has said its own systems were not affected and that no test orders, results or diagnostic information from the company were in the collector's system. "Labcorp was responsible for vetting and managing that vendor," said Connecticut Attorney General William Tong, whose office led the investigation. Labcorp will pay $2,287,455 to the states. Shares published by other states include $81,296 for Connecticut, $43,313 for Pennsylvania and $17,534 for Wisconsin. The money goes to the states, not to consumers. States that need court approval, as Alaska does, receive payment after it is granted. The settlement also requires Labcorp to appoint a chief information security officer and to have an independent firm assess how it manages the security risks of its vendors within 18 months of the Oct. 1 effective date. Its vendor-management requirements last until Oct. 1, 2031. The agreement adds to a 2021 multistate settlement with the debt collector itself, which included a $21 million payment that was suspended because of the collector's bankruptcy. Labcorp has separately agreed to pay $35 million to settle a related class-action lawsuit, which is still ongoing against other companies the collector served. What did you make of this story? (no account needed) Drafted with AI. Edited by Cale Green (1 revision). Reviewed by Cale Green. Who is accountable.

DataBreachToday Asia
Sep 25th, 2026
LabCorp pays states $2.2M in settlement over AMCA hack.

LabCorp pays states $2.2M in settlement over AMCA hack. 42 States, DC Require Lab to Strengthen Security, Vendor Risk Management Practices Marianne Kolbasuk McGee (HealthInfoSec) - September 25, 2026 LabCorp has agreed to pay $2.2 million and improve its data security and vendor risk management practices - especially with debt collectors - to resolve multistate litigation stemming from a 2019 hack on American Medical Collections Agency. The hack affected more than 10.2 million patients of the medical testing lab, and the settlement announced on Thursday resolves a list of claims against North Carolina-based LabCorp involving a variety of state consumer protection and personal information protection laws, as well violations of federal laws, including HIPAA. Under the HITECH Act of 2009, state attorneys general were granted the right to pursue federal HIPAA violations. Retrieval-Masters Creditors Bureau, a then-42-year-old New York business operating under the name American Medical Collection Agency, or AMCA, filed for bankruptcy just weeks after discovering the breach in 2019 and ultimately went out of business. Besides LabCorp, the AMCA hack affected dozens of the firm's other clients and about 27.5 million people nationwide. "Companies entrusted with consumers' sensitive health and personal information remain responsible for protecting that information when they share it with outside vendors," said Jennifer Davenport, attorney general of New Jersey, where 417,308 LabCorp patients were affected by the AMCA hack. "Businesses cannot outsource their obligation to safeguard consumer data. This settlement reinforces the importance of carefully vetting vendors and maintaining strong oversight to ensure the information entrusted to them remains secure," Davenport said. Under the settlement, LabCorp will pay New Jersey $68,000. The financial settlement also will be divided in varying amounts among the other states. Besides the financial payments, LabCorp has agreed to overhaul its data security and vendor risk management practices. That includes employing a CISO - an executive or officer "with appropriate credentials, background and expertise in information security who shall be responsible for overseeing the implementation and maintenance" of the bolstered information security program, according to the settlement. LabCorp also is required to minimize the amount of data shared with vendors; expand its vendor risk management program, including establishing a dedicated team, using tools to evaluate vendors; and verify that vendors comply with security requirements. The plan also calls for LabCorp to impose additional requirements on debt-collection vendors including maintaining inventories of contracts; putting cybersecurity requirements into contracts; segmenting LabCorp data from information debt collectors hold for other clients; requiring collectors to conduct security assessments and audits; and giving LabCorp the contractual right to terminate vendors for noncompliance. "Covered entity responsibility for the actions of their business associates is a longstanding area of concern," said regulatory attorney David Holtzman, retired founder of consulting firm HITprivacy. When the HIPAA Security Rule was first enacted in 2005, it allowed covered organizations - such as medical testing labs, hospitals and clinics - "to take a hands-off approach to how their vendors and contractors handled protected health information," Holtzman said. The HITECH Act extended direct HIPAA compliance liability to business associates, but that "only goes so far," Holtzman said, who was also previously an adviser in the U.S. Department of Health and Human Services' Office for Civil Rights, which oversees federal HIPAA enforcement. "HHS can solve this problem through regulatory action to extend reasonable vendor management standards to covered entities and business associates that engage subcontractors," Holtzman added. The settlement with the state attorneys general also comes on the heels of LabCorp agreeing in June to pay $35 million to settle proposed civil class action litigation related to the AMCA incident. Under that agreement, LabCorp also said it would improve its data security practices (see: LabCorp Agrees to Pay $35M to Settle AMCA Data Breach). A coalition of 41 state attorneys general in 2021 also reached a $21 million settlement with AMCA in the incident (see: Debt Collection Firm Reaches Breach Settlement With States). AMCA first learned that the company might have a problem when it received a series of "Common Point of Purchase" notices in 2019 suggesting that a disproportionate number of credit cards that at some time had shown up on AMCA's web portal were later associated with fraudulent charges, court documents said. AMCA said it shut down its web portal to prevent any further compromises of customer data and engaged outside consultants who confirmed that AMCA's servers had been hacked as early as August 2018. LabCorp did not immediately respond to ISMG's request for comment on the settlement with the state attorneys general. The 42 states participating in the settlement are Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wisconsin and West Virginia - involved in the settlement - plus Washington D.C.